Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease
- PMID: 19010326
- PMCID: PMC3039001
- DOI: 10.1053/j.gastro.2008.09.018
Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease
Abstract
Background & aims: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of obesity and metabolic syndrome (MetS). Alanine aminotransferase (ALT) levels are used to detect NAFLD and have also been associated with increased risk for MetS, diabetes mellitus, and cardiovascular disease (CVD). We studied the relationship between ALT levels and these disorders in a long-term follow-up study.
Methods: Framingham Offspring Heart Study participants (n = 2812; mean age, 44 years; 56% women) were followed for the development of MetS, diabetes, CVD, and all-cause mortality using logistic regression (MetS, diabetes) or Cox proportional hazards models (CVD, all-cause mortality).
Results: Among individuals at baseline, per 1 standard deviation increase in log ALT level, there were increased odds of the development of MetS (odds ratio [OR] 1.21, P < .001) and diabetes (OR, 1.48; P < .0001) over 20 years of follow-up. These findings also applied to participants with ALT levels within the normal range (MetS OR, 1.17; P = .006; diabetes OR, 1.34; P =.002). There was an increased risk of CVD in age/gender-adjusted models (hazard ratio, 1.23; P < .0001), but this was attenuated in multivariable-adjusted models (hazard ratio 1.05; P = .27); no association was observed for all-cause mortality. Aspartate aminotransferase levels were found to be associated with an increased risk of only diabetes.
Conclusions: Both normal and increased levels of ALT are associated with long-term development of multiple metabolic disorders. These results indicate the potential for ALT values as biomarkers for the risk of metabolic disease.
Figures
Comment in
-
Implications of elevated serum alanine aminotransferase levels: think outside the liver.Gastroenterology. 2008 Dec;135(6):1851-4. doi: 10.1053/j.gastro.2008.11.005. Epub 2008 Nov 11. Gastroenterology. 2008. PMID: 19007778 No abstract available.
Similar articles
-
LV Mass as a Predictor of CVD Events in Older Adults With and Without Metabolic Syndrome and Diabetes.JACC Cardiovasc Imaging. 2015 Sep;8(9):1007-1015. doi: 10.1016/j.jcmg.2015.04.019. Epub 2015 Aug 26. JACC Cardiovasc Imaging. 2015. PMID: 26319502 Free PMC article.
-
Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort.Cardiovasc Diabetol. 2020 Nov 22;19(1):195. doi: 10.1186/s12933-020-01166-6. Cardiovasc Diabetol. 2020. PMID: 33222691 Free PMC article.
-
Longitudinal Changes in Liver Aminotransferases Predict Metabolic Syndrome in Chinese Patients with Nonviral Hepatitis.Biomed Environ Sci. 2016 Apr;29(4):254-66. doi: 10.3967/bes2016.033. Biomed Environ Sci. 2016. PMID: 27241736
-
Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis.J Gastroenterol Hepatol. 2016 May;31(5):936-44. doi: 10.1111/jgh.13264. J Gastroenterol Hepatol. 2016. PMID: 26667191 Review.
-
Prognostic interactions between cardiovascular risk factors.Dan Med J. 2014 Jul;61(7):B4892. Dan Med J. 2014. PMID: 25123126 Review.
Cited by
-
Aminotransferases as causal factors for metabolic syndrome: A bidirectional Mendelian randomization study.PLoS One. 2024 Apr 25;19(4):e0302209. doi: 10.1371/journal.pone.0302209. eCollection 2024. PLoS One. 2024. PMID: 38662679 Free PMC article.
-
The association of ALT to HDL-C ratio with type 2 diabetes in 50-74 years old adults: a population-based study.Sci Rep. 2024 Apr 24;14(1):9390. doi: 10.1038/s41598-024-60092-9. Sci Rep. 2024. PMID: 38658745 Free PMC article.
-
Assessment of the Relationship Between Liver Enzymes and Cardiovascular Disease: A Study in Bangladeshi Adults.Endocrinol Diabetes Metab. 2024 Mar;7(2):e00481. doi: 10.1002/edm2.481. Endocrinol Diabetes Metab. 2024. PMID: 38494432 Free PMC article.
-
Causal associations between liver enzymes and diabetic microvascular complications: A univariable and multivariable Mendelian randomization.PLoS One. 2024 Jan 17;19(1):e0296894. doi: 10.1371/journal.pone.0296894. eCollection 2024. PLoS One. 2024. PMID: 38232082 Free PMC article.
-
AST and ALT APRI Scores and Dysglycemia in Saudi Arabia: A Retrospective Population Study.Life (Basel). 2023 Sep 7;13(9):1881. doi: 10.3390/life13091881. Life (Basel). 2023. PMID: 37763285 Free PMC article.
References
-
- Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–7. - PubMed
-
- Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50. - PubMed
-
- Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–8. - PubMed
-
- Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52. - PubMed
-
- Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical